{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=36", "query": { "condition": "Carcinoma, Pancreas", "page": 36 }, "page_size": 10 }, "pagination": { "page": 36, "page_size": 10, "total_count": 2232, "total_pages": 224, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=37&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Pancreas&page=35&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T09:12:44.838Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01438385", "title": "Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ampullary Cancer", "Duodenal Cancer", "Bile Duct Cancer", "Bile Duct Disorders", "Gallstones", "Obstructive Jaundice", "Pancreatic Disorders (Noncancerous)", "Colorectal Cancer", "Esophageal Cancer", "Barrett's Esophagus", "Gastric Malignancies", "Pancreatic Cancer", "Pediatric Gastroenterology", "Cholangiocarcinoma", "Pancreatic Pseudocysts", "Acute and Chronic Pancreatitis", "Recurrent Pancreatitis", "Cholangitis", "Bile Leak", "Biliary Strictures", "Pancreatic Divisum", "Biliary and Pancreatic Stones", "Choledocholithiasis" ], "interventions": [ { "name": "Interventional Endoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12000, "start_date": "2011-07", "completion_date": "2017-12-30", "has_results": false, "last_update_posted_date": "2017-02-20", "last_synced_at": "2026-10-21T09:12:44.838Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01438385" }, { "nct_id": "NCT02588443", "title": "Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "RO70097890", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2015-10", "completion_date": "2018-11", "has_results": false, "last_update_posted_date": "2022-09-06", "last_synced_at": "2026-10-21T09:12:44.838Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02588443" }, { "nct_id": "NCT06017323", "title": "Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Proglumide Dose level 1", "type": "DRUG" }, { "name": "Proglumide Dose level 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-10", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2023-10-25", "last_synced_at": "2026-10-21T09:12:44.838Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06017323" }, { "nct_id": "NCT00316420", "title": "Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Capecitabine (Xeloda)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Swedish Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2003-12", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2010-03-08", "last_synced_at": "2026-10-21T09:12:44.838Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00316420" }, { "nct_id": "NCT01643460", "title": "Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Cyst", "Pancreatic Intraductal Papillary-Mucinous Neoplasm", "Cystadenoma, Mucinous", "Papillary Mucinous Cystadenoma, Borderline Malignancy" ], "interventions": [ { "name": "98% Ethanol & Paclitaxel injection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2009-09", "completion_date": "2022-03-31", "has_results": false, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-10-21T09:12:44.838Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01643460" }, { "nct_id": "NCT07629960", "title": "A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Non-Small Cell Lung Cancer", "Colorectal Neoplasms", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "BLU-924", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2026-06-04", "completion_date": "2031-07", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-21T09:12:44.838Z", "location_count": 10, "location_summary": "Sarasota, Florida • Tampa, Florida • Baton Rouge, Louisiana + 7 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07629960" }, { "nct_id": "NCT06385925", "title": "A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "TSN1611", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyligand Pharmaceuticals (Suzhou) Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 440, "start_date": "2024-04-29", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-21T09:12:44.838Z", "location_count": 3, "location_summary": "Houston, Texas • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06385925" }, { "nct_id": "NCT03058289", "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "Lymphoma", "Pancreatic Cancer", "Liver Cancer", "Colon Cancer", "Lung Cancer", "Bile Duct Cancer", "Chordoma of Sacrum", "Sarcoma" ], "interventions": [ { "name": "INT230-6", "type": "DRUG" }, { "name": "anti-PD-1 antibody", "type": "BIOLOGICAL" }, { "name": "anti-CTLA-4 antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Intensity Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-02-09", "completion_date": "2023-02-22", "has_results": true, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-10-21T09:12:44.838Z", "location_count": 7, "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03058289" }, { "nct_id": "NCT01456585", "title": "Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma Pancreas" ], "interventions": [ { "name": "Gemcitabine", "type": "OTHER" }, { "name": "CP-870,893", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-04", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2018-08-27", "last_synced_at": "2026-10-21T09:12:44.838Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01456585" }, { "nct_id": "NCT04807972", "title": "Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "ABBV-927", "type": "DRUG" }, { "name": "Budiglimab", "type": "DRUG" }, { "name": "modified FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2021-05-28", "completion_date": "2024-03-25", "has_results": false, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-10-21T09:12:44.838Z", "location_count": 5, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Cleveland, Ohio + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04807972" } ] }